🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells New study by Jonathan Chou Felix Feng Martin Sjöström Ewan Gibb Peter Black Vadim Koshkin MD Sima Porten Maxwell Meng UCSFUrology euoncology.europeanurology.com/article/S2588-…

Important work by Carissa Chu Jonathan Chou UCSF Helen Diller Family Comprehensive Cancer Ctr UCSFUrology focusing on biomarkers of response for targeted agents in #bladdercancer Bladder Cancer Advocacy Network OncoAlert IBCG UroToday.com

Latest work with Rahul Aggarwal, Jim Wells, Felix Feng, Jonathan Chou, Ning Zhao and many other fantastic colleagues showing CDCP1 is a promising candidate for targeted radiotherapy in prostate cancer, including PSMA low/null disease. UCSF Imaging pubmed.ncbi.nlm.nih.gov/35604681/

Exciting new study out of UCSF Helen Diller Family Comprehensive Cancer Ctr Michael Evans Jonathan Chou et al: Theranostic Targeting of CDCP1 in Multiple Subtypes of Bladder Cancer with Lu177 tinyurl.com/4tydrx87

Excited to see our B7-H3 paper published by STM today! Many thanks for all lab members, collaborators and funding sources! @Wei_Shi90 @BradStCroix Ana Aparicio MD Anderson Cancer Center Prostate Cancer Foundation CPRIT NIH science.org/doi/10.1126/sc…

Team UCSF at the 2023 BCAN Think Tank! Blessed to have such amazing colleagues and friends Carissa Chu Vadim Koshkin MD Cornelia Ding, MD, PhD SamWashUro Heiko Yang #BCANTT23

Awesome showing by UCSF Helen Diller Family Comprehensive Cancer Ctr at #BCANTT23 Thank you to Sima Porten and many of our colleagues UCSF Health including also @friedt02 Tanya Jindal Jonathan Chou Xiaolin Zhu @HemoncUcsf Cornelia Ding, MD, PhD and our NPs Iva Colon and Krisztina Emodi Bladder Cancer Advocacy Network

Simon C Journal of Clinical Oncology Paolo Tarantino ASCO UroToday.com OncoAlert Top Biomedical Science Markus Eckstein Thanks Simon C We and others (aacrjournals.org/clincancerres/…) believe yes: Membranous NECTIN4 expression is correlated to EV response. Further, app. 40% of oUC metastatic samples are lacking membranous NECTIN4 aacrjournals.org/clincancerres/…

Nectin4 amplification predicts response to enfortumab vedotin in metastatic urothelial carcinoma - Paolo Tarantino Niklas Klümper #BreastCancer #DanaFarberCancerInstitute #GU24 #HER2 #ExperimentalOncology #LungCancer oncodaily.com/32899.html

Great overview on UC pathology Markus Eckstein 🔥 important to keep these pathways of UC carcinogenesis in mind for ADC targets as well, as NECTIN4 is overexpressed in luminal tumors as nicely demonstrated by Jonathan Chou pubmed.ncbi.nlm.nih.gov/34108177/ in Clinical Cancer Research UroToday.com OncoAlert

Our latest paper ist out in Histopathology ! We comprehensively studied the membranous protein expression of the two important #ADC targets TROP2 and NECTIN4 (surfaceome 🏄‍♂️). it is the first paper on protein expression in a large cohort of over 200 muscle-invasive and metastic

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered

Histologic variants in bladder cancer harbor aggressive molecular features including TM4SF1 expression and a CA125+ cell state biorxiv.org/cgi/content/sh… #biorxiv_cancer

Awesome #BCANTT24 this year. Great representation from #UCSF!

In prostate cancer, sensitivity to poly ADP-ribose polymerase inhibitors is dependent on the specific type and zygosity of the CDK12 mutation, reports Dr. Jonathan Chou's team at UC San Francisco. bit.ly/3zBmdzq

Thanks Jonathan Chou for visiting Fred Hutch Cancer Center fantastic talk & dinner! Hsieh Lab Haolong Li Omar Mian Jonathan L Wright Vadim Koshkin MD Gavin Ha Terry Friedlander Bladder Cancer Advocacy Network Uromigos Joshua Meeks Tian Zhang, MD, MHS Lee Lab Dr. Bishoy M. Faltas Great opportunities for collaboration & translation!

🔥 Hot off the press: Lixing Yang, PhD, and collaborators at UC San Francisco have published a ground breaking work in Nature Cancer, demonstrating how unrepaired collision of DNA replication and transcription can drive aggressive cancers. UChicago Committee on Cancer Biology Jonathan Chou ow.ly/VkTT50U9bYt

📕 New publication alert: Lixing Yang, PhD and his collaborators at UC San Francisco published an exciting work demonstrating new approaches to correct the errors generated by the collision of DNA replication and transcription. Jonathan Chou Nature Cancer UChicago Committee on Cancer Biology ow.ly/QEtK50UahjS

📢Check out this Article NOW ONLINE! Nature Cancer '#Transcription and #DNAreplication collisions lead to large tandem duplications and expose targetable #therapeutic vulnerabilities in #cancer' ✏️By Jonathan Chou, Lixing Yang and colleagues 📎nature.com/articles/s4301…

UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡Stephanie Chisolm, PhD UCSF Helen Diller Family Comprehensive Cancer Ctr UCSFUrology Sima Porten Jonathan Chou Vadim Koshkin MD SamWashUro